Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 424 participants.

Also called NCT04373967

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 424 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04373967
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04373967. Randomized; no masking; primary purpose treatment. Start 2020-04-29 (actual); primary completion 2021-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Intervention (Drug)
Victoza®.
Intervention (Drug)
Metformin Hydrochloride
Intervention (Drug)
TQZ2451
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04373967
Content hash
d13073b0f3e7646487287973468b17de60c8b53a8cc63a4e2f5d6f043d14a305